You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePerindopril
Accession NumberDB00790  (APRD01178)
TypeSmall Molecule
GroupsApproved
DescriptionPerindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Perindopril may be used to treat mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.
Structure
Thumb
Synonyms
(2S,3AS,7as)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acid
Perindoprilum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Aceontablet2 mg/1oralXOMA (US) LLC1993-12-30Not applicableUs
Aceontablet2 mg/1oralSymplmed, LLC2014-10-10Not applicableUs
Aceontablet4 mg/1oralXOMA (US) LLC1993-12-30Not applicableUs
Aceontablet4 mg/1oralSymplmed, LLC2014-10-10Not applicableUs
Aceontablet8 mg/1oralXOMA (US) LLC1993-12-30Not applicableUs
Aceontablet8 mg/1oralSymplmed, LLC2014-10-10Not applicableUs
Arcosyltablet (orally disintegrating)10 mgoralServier Canada IncNot applicableNot applicableCanada
Arcosyltablet5 mgoralServier Canada IncNot applicableNot applicableCanada
Arcosyltablet10 mgoralServier Canada IncNot applicableNot applicableCanada
Arcosyltablet (orally disintegrating)2.5 mgoralServier Canada IncNot applicableNot applicableCanada
Arcosyltablet2.5 mgoralServier Canada IncNot applicableNot applicableCanada
Arcosyltablet (orally disintegrating)5 mgoralServier Canada IncNot applicableNot applicableCanada
Coversyltablet4 mgoralServier Canada Inc1994-12-31Not applicableCanada
Coversyltablet2 mgoralServier Canada Inc1994-12-31Not applicableCanada
Coversyltablet8 mgoralServier Canada Inc2003-09-11Not applicableCanada
Perindopril Erbuminetablet4 mg/1oralLannett Company, Inc.2014-10-01Not applicableUs
Perindopril Erbuminetablet8 mg/1oralLannett Company, Inc.2014-10-01Not applicableUs
Perindopril Erbuminetablet4 mg/1oralMarlex Pharmaceuticals Inc2015-05-01Not applicableUs
Perindopril Erbuminetablet8 mg/1oralMarlex Pharmaceuticals Inc2015-05-01Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-perindopriltablet8 mgoralApotex Inc2007-02-02Not applicableCanada
Perindopril Erbuminetablet4 mg/1oralLupin Pharmaceuticals, Inc2010-03-15Not applicableUs
Perindopril Erbuminetablet2 mg/1oralRoxane Laboratories, Inc.2009-11-10Not applicableUs
Perindopril Erbuminetablet4 mg/1oralAurobindo Pharma Limited2009-11-10Not applicableUs
Perindopril Erbuminetablet8 mg/1oralLupin Pharmaceuticals, Inc2010-03-15Not applicableUs
Perindopril Erbuminetablet4 mg/1oralRoxane Laboratories, Inc.2009-11-10Not applicableUs
Perindopril Erbuminetablet8 mg/1oralAurobindo Pharma Limited2009-11-10Not applicableUs
Perindopril Erbuminetablet8 mg/1oralRoxane Laboratories, Inc.2009-11-10Not applicableUs
Perindopril Erbuminetablet2 mg/1oralLupin Pharmaceuticals, Inc2010-03-15Not applicableUs
Perindopril Erbuminetablet2 mg/1oralAurobindo Pharma Limited2009-11-10Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CoversylServier
Brand mixtures
NameLabellerIngredients
Arcosyl PlusServier Canada Inc
Arcosyl Plus LdServier Canada Inc
Coversyl PlusServier Canada Inc
Coversyl Plus HdServier Canada Inc
Coversyl Plus LdServier Canada Inc
PrestaliaSymplmed Pharmaceuticals, Llc
ViacoramServier Canada Inc
Salts
Name/CASStructureProperties
Perindopril arginine
612548-45-5
Thumb
  • InChI Key: RYCSJJXKEWBUTI-YDYAIEMNSA-N
  • Monoisotopic Mass: 542.342797845
  • Average Mass: 542.678
DBSALT001144
Perindopril erbumine
107133-36-8
Thumb
  • InChI Key: IYNMDWMQHSMDDE-MHXJNQAMSA-N
  • Monoisotopic Mass: 441.320271497
  • Average Mass: 441.613
DBSALT001145
Categories
UNIIY5GMK36KGY
CAS number82834-16-0
WeightAverage: 368.4678
Monoisotopic: 368.231122144
Chemical FormulaC19H32N2O5
InChI KeyInChIKey=IPVQLZZIHOAWMC-QXKUPLGCSA-N
InChI
InChI=1S/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16,20H,4-11H2,1-3H3,(H,23,24)/t12-,13-,14-,15-,16-/m0/s1
IUPAC Name
(2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]-octahydro-1H-indole-2-carboxylic acid
SMILES
[H][C@]12C[[email protected]](N(C(=O)[[email protected]](C)N[C@@H](CCC)C(=O)OCC)[C@@]1([H])CCCC2)C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as peptides. These are compounds containing an amide derived from two or more amino carboxylic acid molecules (the same or different) by formation of a covalent bond from the carbonyl carbon of one to the nitrogen atom of another.
KingdomOrganic compounds
Super ClassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
Sub ClassAmino acids, peptides, and analogues
Direct ParentPeptides
Alternative Parents
Substituents
  • Alpha peptide
  • N-acyl-alpha amino acid or derivatives
  • N-acyl-alpha-amino acid
  • Alpha-amino acid ester
  • Alpha-amino acid amide
  • Alpha-amino acid or derivatives
  • N-substituted-alpha-amino acid
  • Indole or derivatives
  • Pyrrolidine carboxylic acid or derivatives
  • Pyrrolidine carboxylic acid
  • N-acylpyrrolidine
  • Fatty acid ester
  • Fatty acyl
  • Dicarboxylic acid or derivatives
  • Tertiary carboxylic acid amide
  • Pyrrolidine
  • Tertiary amine
  • Carboxylic acid ester
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aliphatic heteropolycyclic compound
Molecular FrameworkAliphatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.
PharmacodynamicsPerindopril is a nonsulfhydryl prodrug that is metabolized via first pass effect (62%) and systemic hydrolysis (38%) to perindoprilat, its active metabolite, following oral administration. Perindoprilat lowers blood pressure by antagonizing the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may sustain the effects of perindoprilat by causing increased vasodilation and decreased blood pressure.
Mechanism of actionThere are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Perindoprilat, the active metabolite of perindopril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Perindopril also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.
Related Articles
AbsorptionRapidly absorbed with peak plasma concentrations occurring approximately 1 hour after oral administration. Bioavailability is 65-75%. Following absorption, perindopril is hydrolyzed to perindoprilat, which has an average bioavailability of 20%. The rate and extent of absorption is unaffected by food. However, food decreases the extent of biotransformation to peridoprilat and reduces its bioavailability by 35%.
Volume of distributionNot Available
Protein bindingPerindoprilat, 10-20% bound to plasma proteins
Metabolism

Extensively metabolized, with only 4-12% of the dose recovered in urine following oral administration. Six metabolites have been identified: perindoprilat, perindopril glucuronide, perindoprilat glucuronide, a perindopril lactam, and two perindoprilat lactams. Only perindoprilat is pharmacologically active. Peridoprilat and perindoprilat glucuronide are the two main circulating metabolites.

SubstrateEnzymesProduct
Perindopril
Not Available
Perindopril Acyl-beta-D-glucuronideDetails
Perindopril
Not Available
PerindoprilatDetails
Perindopril
Not Available
Perindoprilat glucuronideDetails
Route of eliminationPerindopril is extensively metabolized following oral administration, with only 4 to 12% of the dose recovered unchanged in the urine.
Half lifePerindopril, 1.2 hours; Peridoprilat, 30-120 hours. The long half life of peridoprilat is due to its slow dissociation from ACE binding sites.
Clearance
  • 219 – 362 mL/min [oral administration]
ToxicityThe most likely symptom of overdose is severe hypotension. The most common adverse effects observed in controlled clinical trials include cough, digestive symptoms, fatigue, headache, and dizziness.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Perindopril Action PathwayDrug actionSMP00152
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9156
Blood Brain Barrier-0.8411
Caco-2 permeable-0.7871
P-glycoprotein substrateSubstrate0.6826
P-glycoprotein inhibitor IInhibitor0.5
P-glycoprotein inhibitor IIInhibitor0.8589
Renal organic cation transporterNon-inhibitor0.919
CYP450 2C9 substrateNon-substrate0.8638
CYP450 2D6 substrateNon-substrate0.8542
CYP450 3A4 substrateSubstrate0.549
CYP450 1A2 substrateNon-inhibitor0.8796
CYP450 2C9 inhibitorNon-inhibitor0.8612
CYP450 2D6 inhibitorNon-inhibitor0.9088
CYP450 2C19 inhibitorNon-inhibitor0.8375
CYP450 3A4 inhibitorNon-inhibitor0.7142
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5951
Ames testNon AMES toxic0.8814
CarcinogenicityNon-carcinogens0.9266
BiodegradationNot ready biodegradable0.9082
Rat acute toxicity1.9432 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9839
hERG inhibition (predictor II)Non-inhibitor0.8678
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Abbott products inc
  • Aurobindo pharma ltd
  • Ivax pharmaceuticals inc
  • Lupin ltd
  • Roxane laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral8 mg
Tabletoral10 mg
Tabletoral2.5 mg
Tabletoral5 mg
Tablet (orally disintegrating)oral10 mg
Tablet (orally disintegrating)oral2.5 mg
Tablet (orally disintegrating)oral5 mg
Tabletoral2 mg
Tabletoral4 mg
Tabletoral2 mg/1
Tabletoral4 mg/1
Tabletoral8 mg/1
Tabletoral
Prices
Unit descriptionCostUnit
Aceon 8 mg tablet3.14USD tablet
Perindopril erbumine 8 mg tablet2.8USD tablet
Aceon 4 mg tablet2.58USD tablet
Perindopril erbumine 4 mg tablet2.3USD tablet
Aceon 2 mg tablet2.22USD tablet
Perindopril erbumine 2 mg tablet1.98USD tablet
Coversyl 8 mg Tablet1.23USD tablet
Coversyl 4 mg Tablet0.88USD tablet
Coversyl 2 mg Tablet0.7USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1341196 No2001-03-062018-03-06Canada
CA2473205 No2010-05-182023-01-22Canada
US5162362 No1992-11-102009-11-10Us
US6696481 No2003-04-152023-04-15Us
US7846961 No2009-10-052029-10-05Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP2.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.22 mg/mLALOGPS
logP0.56ALOGPS
logP0.63ChemAxon
logS-2.5ALOGPS
pKa (Strongest Acidic)3.79ChemAxon
pKa (Strongest Basic)5.48ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area95.94 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity95.69 m3·mol-1ChemAxon
Polarizability40 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Michel Vincent, Jean Baliarda, Bernard Marchand, Georges Remond, “Process for the industrial synthesis of perindopril.” U.S. Patent US4914214, issued April 03, 1990.

US4914214
General References
  1. Hurst M, Jarvis B: Perindopril: an updated review of its use in hypertension. Drugs. 2001;61(6):867-96. [PubMed:11398915 ]
  2. Jastrzebskal M, Widecka K, Naruszewicz M, Ciechanowicz A, Janczak-Bazan A, Foltynska A, Goracy I, Chetstowski K, Wesotowska T: Effects of perindopril treatment on hemostatic function in patients with essential hypertension in relation to angiotensin converting enzyme (ACE) and plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms. Nutr Metab Cardiovasc Dis. 2004 Oct;14(5):259-69. [PubMed:15673060 ]
  3. Parker E, Aarons L, Rowland M, Resplandy G: The pharmacokinetics of perindoprilat in normal volunteers and patients: influence of age and disease state. Eur J Pharm Sci. 2005 Sep;26(1):104-13. [PubMed:15982858 ]
  4. Simpson D, Noble S, Goa KL: Perindopril: in congestive heart failure. Drugs. 2002;62(9):1367-77; discussion 1378-9. [PubMed:12076191 ]
  5. Yasumatsu R, Nakashima T, Masuda M, Ito A, Kuratomi Y, Nakagawa T, Komune S: Effects of the angiotensin-I converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol. 2004 Oct;130(10):567-73. Epub 2004 Jul 27. [PubMed:15449186 ]
  6. Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R, Nakatani T, Tsujinoue H, Fukui H: The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res. 2001 Apr;7(4):1073-8. [PubMed:11309359 ]
External Links
ATC CodesC10BX11C09AA04C09BX02C09BA04C09BB04C09BX01
AHFS Codes
  • 24:32.04
PDB EntriesNot Available
FDA labelDownload (149 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Perindopril.
AbacavirThe serum concentration of Abacavir can be decreased when it is combined with Perindopril.
AcebutololPerindopril may increase the hypotensive activities of Acebutolol.
AceclofenacThe risk or severity of adverse effects can be increased when Perindopril is combined with Aceclofenac.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Perindopril.
AcetazolamideThe risk or severity of adverse effects can be increased when Perindopril is combined with Acetazolamide.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Perindopril is combined with Acetylsalicylic acid.
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Perindopril.
AdapaleneThe risk or severity of adverse effects can be increased when Perindopril is combined with Adapalene.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Perindopril.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Perindopril.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Perindopril.
AlfuzosinAlfuzosin may increase the hypotensive activities of Perindopril.
AlfuzosinThe serum concentration of Alfuzosin can be increased when it is combined with Perindopril.
AliskirenPerindopril may increase the hypotensive activities of Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Perindopril.
AllopurinolThe risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Perindopril.
AlogliptinThe risk or severity of adverse effects can be increased when Alogliptin is combined with Perindopril.
AlprazolamThe serum concentration of Alprazolam can be increased when it is combined with Perindopril.
AlprenololPerindopril may increase the hypotensive activities of Alprenolol.
AmbrisentanPerindopril may increase the hypotensive activities of Ambrisentan.
AmifostinePerindopril may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Amiloride is combined with Perindopril.
AmineptineThe serum concentration of Amineptine can be increased when it is combined with Perindopril.
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Perindopril.
Aminosalicylic AcidAminosalicylic Acid may decrease the antihypertensive activities of Perindopril.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Perindopril.
AmlodipineAmlodipine may increase the hypotensive activities of Perindopril.
AmobarbitalAmobarbital may increase the hypotensive activities of Perindopril.
Amyl NitriteThe risk or severity of adverse effects can be increased when Perindopril is combined with Amyl Nitrite.
AntipyrineThe risk or severity of adverse effects can be increased when Perindopril is combined with Antipyrine.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Perindopril.
ApraclonidineThe risk or severity of adverse effects can be increased when Perindopril is combined with Apraclonidine.
ApremilastThe risk or severity of adverse effects can be increased when Perindopril is combined with Apremilast.
AprotininAprotinin may decrease the antihypertensive activities of Perindopril.
ArdeparinArdeparin may increase the hyperkalemic activities of Perindopril.
AripiprazoleAripiprazole may increase the hypotensive activities of Perindopril.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Perindopril.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Perindopril.
AtenololAtenolol may increase the hypotensive activities of Perindopril.
AtorvastatinThe serum concentration of Atorvastatin can be increased when it is combined with Perindopril.
AtorvastatinThe risk or severity of adverse effects can be increased when Atorvastatin is combined with Perindopril.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Perindopril.
AzapropazoneThe risk or severity of adverse effects can be increased when Perindopril is combined with Azapropazone.
AzathioprinePerindopril may increase the myelosuppressive activities of Azathioprine.
AzelastineThe risk or severity of adverse effects can be increased when Perindopril is combined with Azelastine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Perindopril is combined with Azilsartan medoxomil.
BalsalazideThe risk or severity of adverse effects can be increased when Perindopril is combined with Balsalazide.
BarbitalBarbital may increase the hypotensive activities of Perindopril.
BemiparinBemiparin may increase the hyperkalemic activities of Perindopril.
BenazeprilBenazepril may increase the hypotensive activities of Perindopril.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Perindopril.
BenmoxinBenmoxin may increase the hypotensive activities of Perindopril.
BenoxaprofenThe risk or severity of adverse effects can be increased when Perindopril is combined with Benoxaprofen.
BepridilPerindopril may increase the hypotensive activities of Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Perindopril.
BetaxololBetaxolol may increase the hypotensive activities of Perindopril.
BethanidineBethanidine may increase the hypotensive activities of Perindopril.
BimatoprostPerindopril may increase the hypotensive activities of Bimatoprost.
BisoprololBisoprolol may increase the hypotensive activities of Perindopril.
BoceprevirThe serum concentration of Perindopril can be decreased when it is combined with Boceprevir.
BoceprevirThe serum concentration of Boceprevir can be increased when it is combined with Perindopril.
BosentanBosentan may increase the hypotensive activities of Perindopril.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Perindopril.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Perindopril.
BretyliumPerindopril may increase the hypotensive activities of Bretylium.
BrimonidinePerindopril may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Perindopril.
BromfenacThe risk or severity of adverse effects can be increased when Perindopril is combined with Bromfenac.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Perindopril.
BumetanideThe risk or severity of adverse effects can be increased when Perindopril is combined with Bumetanide.
BupranololPerindopril may increase the hypotensive activities of Bupranolol.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Perindopril.
CabergolineThe serum concentration of Cabergoline can be increased when it is combined with Perindopril.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Perindopril.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Perindopril.
CanagliflozinCanagliflozin may increase the hyperkalemic activities of Perindopril.
CanagliflozinThe risk or severity of adverse effects can be increased when Perindopril is combined with Canagliflozin.
CandesartanPerindopril may increase the hypotensive activities of Candesartan.
CandoxatrilCandoxatril may increase the hypotensive activities of Perindopril.
CaptoprilPerindopril may increase the hypotensive activities of Captopril.
CarbamazepineThe metabolism of Perindopril can be increased when combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Perindopril.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Perindopril.
CaroxazoneCaroxazone may increase the hypotensive activities of Perindopril.
CarprofenThe risk or severity of adverse effects can be increased when Perindopril is combined with Carprofen.
CarteololCarteolol may increase the hypotensive activities of Perindopril.
CarvedilolPerindopril may increase the hypotensive activities of Carvedilol.
CastanospermineThe risk or severity of adverse effects can be increased when Perindopril is combined with Castanospermine.
CelecoxibThe risk or severity of adverse effects can be increased when Perindopril is combined with Celecoxib.
CeliprololPerindopril may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Perindopril.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Perindopril.
CertoparinCertoparin may increase the hyperkalemic activities of Perindopril.
ChloroquineThe risk or severity of adverse effects can be increased when Perindopril is combined with Chloroquine.
ChlorothiazidePerindopril may increase the hypotensive activities of Chlorothiazide.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Perindopril.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Perindopril.
CilazaprilPerindopril may increase the hypotensive activities of Cilazapril.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Perindopril.
CiprofloxacinPerindopril may increase the arrhythmogenic activities of Ciprofloxacin.
CisaprideThe serum concentration of Cisapride can be increased when it is combined with Perindopril.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Perindopril.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Perindopril.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Perindopril.
ClevidipineThe risk or severity of adverse effects can be increased when Perindopril is combined with Clevidipine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Perindopril.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Perindopril.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Perindopril.
ClonidineClonidine may increase the hypotensive activities of Perindopril.
ClonixinThe risk or severity of adverse effects can be increased when Perindopril is combined with Clonixin.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Perindopril.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Perindopril.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Perindopril.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Perindopril.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Perindopril.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Perindopril.
CryptenamineCryptenamine may increase the hypotensive activities of Perindopril.
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be increased when it is combined with Perindopril.
CyclophosphamideThe risk or severity of adverse effects can be increased when Perindopril is combined with Cyclophosphamide.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Perindopril.
CyclothiazideCyclothiazide may increase the hypotensive activities of Perindopril.
D-LimoneneThe risk or severity of adverse effects can be increased when Perindopril is combined with D-Limonene.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Perindopril.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Perindopril.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Perindopril.
DalteparinDalteparin may increase the hyperkalemic activities of Perindopril.
DapagliflozinThe risk or severity of adverse effects can be increased when Perindopril is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Perindopril.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Perindopril.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Perindopril.
DebrisoquinPerindopril may increase the hypotensive activities of Debrisoquin.
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Perindopril.
DeserpidinePerindopril may increase the hypotensive activities of Deserpidine.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Perindopril.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Perindopril.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Perindopril.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Perindopril.
DiazoxideDiazoxide may increase the hypotensive activities of Perindopril.
DiclofenacThe risk or severity of adverse effects can be increased when Perindopril is combined with Diclofenac.
DiclofenamideThe risk or severity of adverse effects can be increased when Perindopril is combined with Diclofenamide.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Perindopril.
DiflunisalThe risk or severity of adverse effects can be increased when Perindopril is combined with Diflunisal.
DiflunisalDiflunisal may decrease the antihypertensive activities of Perindopril.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Perindopril.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Perindopril.
DihydroergotamineThe serum concentration of Dihydroergotamine can be increased when it is combined with Perindopril.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Perindopril.
DiltiazemDiltiazem may increase the hypotensive activities of Perindopril.
DinutuximabThe risk or severity of adverse effects can be increased when Perindopril is combined with Dinutuximab.
DipyridamoleThe risk or severity of adverse effects can be increased when Perindopril is combined with Dipyridamole.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Perindopril.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Perindopril.
DorzolamidePerindopril may increase the hypotensive activities of Dorzolamide.
DosulepinThe serum concentration of Dosulepin can be increased when it is combined with Perindopril.
DoxazosinDoxazosin may increase the hypotensive activities of Perindopril.
DoxepinThe serum concentration of Doxepin can be increased when it is combined with Perindopril.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Perindopril.
DrospirenonePerindopril may increase the hyperkalemic activities of Drospirenone.
DroxicamThe risk or severity of adverse effects can be increased when Perindopril is combined with Droxicam.
DuloxetinePerindopril may increase the orthostatic hypotensive activities of Duloxetine.
DyphyllineThe serum concentration of Dyphylline can be decreased when it is combined with Perindopril.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Perindopril.
EfonidipinePerindopril may increase the hypotensive activities of Efonidipine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Perindopril.
EmpagliflozinThe risk or severity of adverse effects can be increased when Perindopril is combined with Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Perindopril.
EnalaprilatPerindopril may increase the hypotensive activities of Enalaprilat.
EnfuvirtideThe serum concentration of Enfuvirtide can be increased when it is combined with Perindopril.
EnoxaparinEnoxaparin may increase the hyperkalemic activities of Perindopril.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Perindopril.
EpirizoleThe risk or severity of adverse effects can be increased when Perindopril is combined with Epirizole.
EplerenoneEplerenone may increase the hyperkalemic activities of Perindopril.
EplerenoneThe risk or severity of adverse effects can be increased when Perindopril is combined with Eplerenone.
EpoprostenolPerindopril may increase the hypotensive activities of Epoprostenol.
EprosartanPerindopril may increase the hypotensive activities of Eprosartan.
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be increased when it is combined with Perindopril.
ErgonovineThe serum concentration of Ergonovine can be increased when it is combined with Perindopril.
ErgotamineThe serum concentration of Ergotamine can be increased when it is combined with Perindopril.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Perindopril.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Perindopril.
EsmirtazapineThe serum concentration of Esmirtazapine can be increased when it is combined with Perindopril.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Perindopril.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Perindopril.
EstriolThe serum concentration of Estriol can be increased when it is combined with Perindopril.
EstroneThe serum concentration of Estrone can be increased when it is combined with Perindopril.
Etacrynic acidThe risk or severity of adverse effects can be increased when Perindopril is combined with Etacrynic acid.
EtanerceptThe risk or severity of adverse effects can be increased when Perindopril is combined with Etanercept.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Perindopril.
EtodolacThe risk or severity of adverse effects can be increased when Perindopril is combined with Etodolac.
EtofenamateThe risk or severity of adverse effects can be increased when Perindopril is combined with Etofenamate.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Perindopril.
EtoricoxibThe risk or severity of adverse effects can be increased when Perindopril is combined with Etoricoxib.
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Perindopril.
Evening primrose oilThe risk or severity of adverse effects can be increased when Perindopril is combined with Evening primrose oil.
EverolimusThe risk or severity of adverse effects can be increased when Everolimus is combined with Perindopril.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Perindopril.
exisulindThe risk or severity of adverse effects can be increased when Perindopril is combined with exisulind.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Perindopril.
FelodipinePerindopril may increase the hypotensive activities of Felodipine.
FenbufenThe risk or severity of adverse effects can be increased when Perindopril is combined with Fenbufen.
FenoldopamPerindopril may increase the hypotensive activities of Fenoldopam.
FenoprofenThe risk or severity of adverse effects can be increased when Perindopril is combined with Fenoprofen.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Perindopril.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Perindopril.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Perindopril.
FloctafenineThe risk or severity of adverse effects can be increased when Perindopril is combined with Floctafenine.
FlunixinThe risk or severity of adverse effects can be increased when Perindopril is combined with Flunixin.
FlurbiprofenThe risk or severity of adverse effects can be increased when Perindopril is combined with Flurbiprofen.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Perindopril.
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Perindopril.
FosinoprilFosinopril may increase the hypotensive activities of Perindopril.
FurazolidoneFurazolidone may increase the hypotensive activities of Perindopril.
FurosemideThe risk or severity of adverse effects can be increased when Furosemide is combined with Perindopril.
GarlicThe serum concentration of Perindopril can be decreased when it is combined with Garlic.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Perindopril.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Perindopril.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Perindopril.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Perindopril.
GuanabenzGuanabenz may increase the hypotensive activities of Perindopril.
GuanadrelGuanadrel may increase the hypotensive activities of Perindopril.
GuanethidinePerindopril may increase the hypotensive activities of Guanethidine.
GuanfacinePerindopril may increase the hypotensive activities of Guanfacine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Perindopril.
HeparinHeparin may increase the hyperkalemic activities of Perindopril.
HexamethoniumPerindopril may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Perindopril.
HMPL-004The risk or severity of adverse effects can be increased when Perindopril is combined with HMPL-004.
HydracarbazineHydracarbazine may increase the hypotensive activities of Perindopril.
HydralazinePerindopril may increase the hypotensive activities of Hydralazine.
HydrochlorothiazidePerindopril may increase the hypotensive activities of Hydrochlorothiazide.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Perindopril.
HydroflumethiazideHydroflumethiazide may increase the hypotensive activities of Perindopril.
IbuprofenThe risk or severity of adverse effects can be increased when Perindopril is combined with Ibuprofen.
IbuproxamThe risk or severity of adverse effects can be increased when Perindopril is combined with Ibuproxam.
IcatibantIcatibant may decrease the antihypertensive activities of Perindopril.
IcatibantThe risk or severity of adverse effects can be increased when Perindopril is combined with Icatibant.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Perindopril.
IloprostIloprost may increase the hypotensive activities of Perindopril.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Perindopril.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Perindopril.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Perindopril.
IndapamidePerindopril may increase the hypotensive activities of Indapamide.
IndenololPerindopril may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Perindopril.
IndomethacinThe risk or severity of adverse effects can be increased when Perindopril is combined with Indomethacin.
IndoprofenThe risk or severity of adverse effects can be increased when Perindopril is combined with Indoprofen.
IndoraminPerindopril may increase the hypotensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Perindopril.
IproniazidIproniazid may increase the hypotensive activities of Perindopril.
IrbesartanPerindopril may increase the hypotensive activities of Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Perindopril.
IronThe risk or severity of adverse effects can be increased when Perindopril is combined with Iron.
Iron DextranThe risk or severity of adverse effects can be increased when Perindopril is combined with Iron Dextran.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Perindopril.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Perindopril is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Perindopril is combined with Isosorbide Mononitrate.
IsoxicamThe risk or severity of adverse effects can be increased when Perindopril is combined with Isoxicam.
IsoxsuprineThe risk or severity of adverse effects can be increased when Perindopril is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Perindopril.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Perindopril.
KebuzoneThe risk or severity of adverse effects can be increased when Perindopril is combined with Kebuzone.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Perindopril.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Perindopril.
KetoprofenThe risk or severity of adverse effects can be increased when Perindopril is combined with Ketoprofen.
KetorolacThe risk or severity of adverse effects can be increased when Perindopril is combined with Ketorolac.
LabetalolLabetalol may increase the hypotensive activities of Perindopril.
LacidipinePerindopril may increase the hypotensive activities of Lacidipine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Perindopril.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Perindopril.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Perindopril.
Lanthanum carbonateThe serum concentration of Perindopril can be decreased when it is combined with Lanthanum carbonate.
LatanoprostLatanoprost may increase the hypotensive activities of Perindopril.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Perindopril.
LeflunomideThe risk or severity of adverse effects can be increased when Perindopril is combined with Leflunomide.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Perindopril.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Perindopril.
LercanidipineLercanidipine may increase the hypotensive activities of Perindopril.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Perindopril.
LevobunololThe risk or severity of adverse effects can be increased when Perindopril is combined with Levobunolol.
LevodopaPerindopril may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Perindopril.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Perindopril.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Perindopril.
LinagliptinThe risk or severity of adverse effects can be increased when Linagliptin is combined with Perindopril.
LisinoprilLisinopril may increase the hypotensive activities of Perindopril.
LithiumThe serum concentration of Lithium can be increased when it is combined with Perindopril.
LofexidinePerindopril may increase the hypotensive activities of Lofexidine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Perindopril.
LornoxicamThe risk or severity of adverse effects can be increased when Perindopril is combined with Lornoxicam.
LosartanLosartan may increase the hypotensive activities of Perindopril.
LovastatinThe serum concentration of Lovastatin can be increased when it is combined with Perindopril.
LoxoprofenThe risk or severity of adverse effects can be increased when Perindopril is combined with Loxoprofen.
LumiracoxibThe risk or severity of adverse effects can be increased when Perindopril is combined with Lumiracoxib.
MacitentanPerindopril may increase the hypotensive activities of Macitentan.
Magnesium salicylateThe risk or severity of adverse effects can be increased when Perindopril is combined with Magnesium salicylate.
ManidipinePerindopril may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Mannitol is combined with Perindopril.
MasoprocolThe risk or severity of adverse effects can be increased when Perindopril is combined with Masoprocol.
MebanazineMebanazine may increase the hypotensive activities of Perindopril.
MecamylamineMecamylamine may increase the hypotensive activities of Perindopril.
Meclofenamic acidThe risk or severity of adverse effects can be increased when Perindopril is combined with Meclofenamic acid.
Mefenamic acidThe risk or severity of adverse effects can be increased when Perindopril is combined with Mefenamic acid.
MeloxicamThe risk or severity of adverse effects can be increased when Perindopril is combined with Meloxicam.
MesalazineThe risk or severity of adverse effects can be increased when Perindopril is combined with Mesalazine.
MesalazineMesalazine may decrease the antihypertensive activities of Perindopril.
MetamizoleThe risk or severity of adverse effects can be increased when Perindopril is combined with Metamizole.
MethazolamideThe risk or severity of adverse effects can be increased when Methazolamide is combined with Perindopril.
MethohexitalMethohexital may increase the hypotensive activities of Perindopril.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Perindopril.
MethyclothiazideMethyclothiazide may increase the hypotensive activities of Perindopril.
MethyclothiazideThe risk or severity of adverse effects can be increased when Perindopril is combined with Methyclothiazide.
MethyldopaPerindopril may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Perindopril.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Perindopril.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Perindopril.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Perindopril.
MetipranololPerindopril may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Perindopril.
MetoprololMetoprolol may increase the hypotensive activities of Perindopril.
MibefradilPerindopril may increase the hypotensive activities of Mibefradil.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Perindopril.
MinaprineMinaprine may increase the hypotensive activities of Perindopril.
MinoxidilMinoxidil may increase the hypotensive activities of Perindopril.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Perindopril.
MirtazapineThe serum concentration of Mirtazapine can be increased when it is combined with Perindopril.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Perindopril.
MoclobemideMoclobemide may increase the hypotensive activities of Perindopril.
MoexiprilMoexipril may increase the hypotensive activities of Perindopril.
MolsidomineMolsidomine may increase the hypotensive activities of Perindopril.
MorphineThe serum concentration of Morphine can be increased when it is combined with Perindopril.
MoxonidinePerindopril may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Perindopril is combined with Mycophenolate mofetil.
Mycophenolic acidThe risk or severity of adverse effects can be increased when Perindopril is combined with Mycophenolic acid.
NabumetoneThe risk or severity of adverse effects can be increased when Perindopril is combined with Nabumetone.
NadololPerindopril may increase the hypotensive activities of Nadolol.
NadroparinNadroparin may increase the hyperkalemic activities of Perindopril.
NaftifineThe risk or severity of adverse effects can be increased when Perindopril is combined with Naftifine.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Perindopril.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Perindopril.
NaproxenThe risk or severity of adverse effects can be increased when Perindopril is combined with Naproxen.
NCX 4016The risk or severity of adverse effects can be increased when Perindopril is combined with NCX 4016.
NebivololPerindopril may increase the hypotensive activities of Nebivolol.
NefazodoneThe serum concentration of Nefazodone can be increased when it is combined with Perindopril.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Perindopril.
NepafenacThe risk or severity of adverse effects can be increased when Perindopril is combined with Nepafenac.
NesiritideThe risk or severity of adverse effects can be increased when Perindopril is combined with Nesiritide.
NialamideNialamide may increase the hypotensive activities of Perindopril.
NicardipineNicardipine may increase the hypotensive activities of Perindopril.
NicorandilNicorandil may increase the hypotensive activities of Perindopril.
NifedipineThe risk or severity of adverse effects can be increased when Perindopril is combined with Nifedipine.
Niflumic AcidThe risk or severity of adverse effects can be increased when Perindopril is combined with Niflumic Acid.
NiguldipinePerindopril may increase the hypotensive activities of Niguldipine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Perindopril.
NilvadipinePerindopril may increase the hypotensive activities of Nilvadipine.
NimesulideThe risk or severity of adverse effects can be increased when Perindopril is combined with Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Perindopril.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Perindopril.
NisoldipineNisoldipine may increase the hypotensive activities of Perindopril.
NitrendipinePerindopril may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Perindopril.
NitroprussideNitroprusside may increase the hypotensive activities of Perindopril.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Perindopril.
NortriptylineThe serum concentration of Nortriptyline can be increased when it is combined with Perindopril.
ObinutuzumabPerindopril may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Perindopril.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Perindopril.
OlmesartanOlmesartan may increase the hypotensive activities of Perindopril.
OlopatadineThe risk or severity of adverse effects can be increased when Perindopril is combined with Olopatadine.
OlsalazineThe risk or severity of adverse effects can be increased when Perindopril is combined with Olsalazine.
OmapatrilatPerindopril may increase the hypotensive activities of Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Perindopril.
OrgoteinThe risk or severity of adverse effects can be increased when Perindopril is combined with Orgotein.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Perindopril.
OxaprozinThe risk or severity of adverse effects can be increased when Perindopril is combined with Oxaprozin.
OxprenololPerindopril may increase the hypotensive activities of Oxprenolol.
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Perindopril is combined with Oxyphenbutazone.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Perindopril.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Perindopril.
PapaverineThe risk or severity of adverse effects can be increased when Perindopril is combined with Papaverine.
ParecoxibThe risk or severity of adverse effects can be increased when Perindopril is combined with Parecoxib.
PargylinePerindopril may increase the hypotensive activities of Pargyline.
ParnaparinParnaparin may increase the hyperkalemic activities of Perindopril.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Perindopril.
PenbutololPerindopril may increase the hypotensive activities of Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Perindopril.
PentoliniumPerindopril may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Perindopril.
PethidineThe risk or severity of adverse effects can be increased when Perindopril is combined with Pethidine.
PhenelzinePhenelzine may increase the hypotensive activities of Perindopril.
PheniprazinePheniprazine may increase the hypotensive activities of Perindopril.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Perindopril.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Perindopril.
PhenoxybenzaminePerindopril may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Perindopril.
PhentolaminePhentolamine may increase the hypotensive activities of Perindopril.
PhenylbutazoneThe risk or severity of adverse effects can be increased when Perindopril is combined with Phenylbutazone.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Perindopril.
PimecrolimusThe risk or severity of adverse effects can be increased when Perindopril is combined with Pimecrolimus.
PimozideThe serum concentration of Pimozide can be increased when it is combined with Perindopril.
PinacidilPerindopril may increase the hypotensive activities of Pinacidil.
PindololPerindopril may increase the hypotensive activities of Pindolol.
PiretanidePiretanide may increase the hypotensive activities of Perindopril.
PirfenidoneThe risk or severity of adverse effects can be increased when Perindopril is combined with Pirfenidone.
PirlindolePirlindole may increase the hypotensive activities of Perindopril.
PiroxicamThe risk or severity of adverse effects can be increased when Perindopril is combined with Piroxicam.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Perindopril.
PivhydrazinePivhydrazine may increase the hypotensive activities of Perindopril.
PolythiazidePerindopril may increase the hypotensive activities of Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Perindopril.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Perindopril.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Perindopril.
PrazosinPrazosin may increase the hypotensive activities of Perindopril.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Perindopril.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Perindopril.
PregabalinThe risk or severity of adverse effects can be increased when Perindopril is combined with Pregabalin.
PrimidonePrimidone may increase the hypotensive activities of Perindopril.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Perindopril.
PropacetamolThe risk or severity of adverse effects can be increased when Perindopril is combined with Propacetamol.
PropranololPropranolol may increase the hypotensive activities of Perindopril.
ProtriptylineThe serum concentration of Protriptyline can be increased when it is combined with Perindopril.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Perindopril.
PTC299The risk or severity of adverse effects can be increased when Perindopril is combined with PTC299.
QuetiapineThe risk or severity of adverse effects can be increased when Perindopril is combined with Quetiapine.
QuinaprilPerindopril may increase the hypotensive activities of Quinapril.
QuinethazoneQuinethazone may increase the hypotensive activities of Perindopril.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Perindopril.
QuinineQuinine may increase the hypotensive activities of Perindopril.
QuinineThe serum concentration of Quinine can be increased when it is combined with Perindopril.
RamiprilRamipril may increase the hypotensive activities of Perindopril.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Perindopril.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Perindopril.
RasagilineRasagiline may increase the hypotensive activities of Perindopril.
RemikirenRemikiren may increase the hypotensive activities of Perindopril.
RescinnaminePerindopril may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Perindopril.
ResveratrolThe risk or severity of adverse effects can be increased when Perindopril is combined with Resveratrol.
ReviparinReviparin may increase the hyperkalemic activities of Perindopril.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Perindopril.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Perindopril.
RiociguatPerindopril may increase the hypotensive activities of Riociguat.
RisperidonePerindopril may increase the hypotensive activities of Risperidone.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Perindopril.
RituximabPerindopril may increase the hypotensive activities of Rituximab.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Perindopril.
RofecoxibThe risk or severity of adverse effects can be increased when Perindopril is combined with Rofecoxib.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Perindopril.
RosuvastatinThe serum concentration of Rosuvastatin can be increased when it is combined with Perindopril.
SacubitrilThe risk or severity of adverse effects can be increased when Perindopril is combined with Sacubitril.
SafrazineSafrazine may increase the hypotensive activities of Perindopril.
SalicylamideThe risk or severity of adverse effects can be increased when Perindopril is combined with Salicylamide.
Salicylic acidThe risk or severity of adverse effects can be increased when Perindopril is combined with Salicylic acid.
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Perindopril.
SalsalateThe risk or severity of adverse effects can be increased when Perindopril is combined with Salsalate.
SaprisartanPerindopril may increase the hypotensive activities of Saprisartan.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Perindopril.
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Perindopril.
SaxagliptinThe risk or severity of adverse effects can be increased when Saxagliptin is combined with Perindopril.
SecobarbitalSecobarbital may increase the hypotensive activities of Perindopril.
SelegilineSelegiline may increase the hypotensive activities of Perindopril.
SelexipagPerindopril may increase the hypotensive activities of Selexipag.
SeratrodastThe risk or severity of adverse effects can be increased when Perindopril is combined with Seratrodast.
SildenafilThe serum concentration of Sildenafil can be increased when it is combined with Perindopril.
SildenafilSildenafil may increase the antihypertensive activities of Perindopril.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Perindopril.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Perindopril.
SimvastatinThe serum concentration of Simvastatin can be increased when it is combined with Perindopril.
SirolimusThe risk or severity of adverse effects can be increased when Sirolimus is combined with Perindopril.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Perindopril.
SitagliptinThe risk or severity of adverse effects can be increased when Sitagliptin is combined with Perindopril.
SitaxentanPerindopril may increase the hypotensive activities of Sitaxentan.
Sodium aurothiomalateThe risk or severity of adverse effects can be increased when Perindopril is combined with Sodium aurothiomalate.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Perindopril.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Perindopril.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Perindopril.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Perindopril.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Perindopril.
SpiraprilPerindopril may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Perindopril.
SRT501The risk or severity of adverse effects can be increased when Perindopril is combined with SRT501.
St. John's WortThe metabolism of Perindopril can be increased when combined with St. John's Wort.
SulfasalazineThe risk or severity of adverse effects can be increased when Perindopril is combined with Sulfasalazine.
SulindacThe risk or severity of adverse effects can be increased when Perindopril is combined with Sulindac.
SuprofenThe risk or severity of adverse effects can be increased when Perindopril is combined with Suprofen.
TacrolimusThe metabolism of Tacrolimus can be decreased when combined with Perindopril.
TadalafilTadalafil may increase the antihypertensive activities of Perindopril.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Perindopril.
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Perindopril.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Perindopril.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Perindopril.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Perindopril.
TelmisartanPerindopril may increase the hypotensive activities of Telmisartan.
TemocaprilPerindopril may increase the hypotensive activities of Temocapril.
TemsirolimusThe risk or severity of adverse effects can be increased when Temsirolimus is combined with Perindopril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Perindopril.
TenoxicamThe risk or severity of adverse effects can be increased when Perindopril is combined with Tenoxicam.
TepoxalinThe risk or severity of adverse effects can be increased when Perindopril is combined with Tepoxalin.
TerazosinThe risk or severity of adverse effects can be increased when Perindopril is combined with Terazosin.
TeriflunomideThe risk or severity of adverse effects can be increased when Perindopril is combined with Teriflunomide.
TerlipressinPerindopril may increase the hypotensive activities of Terlipressin.
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Perindopril.
ThiamylalThiamylal may increase the hypotensive activities of Perindopril.
ThiopentalThiopental may increase the hypotensive activities of Perindopril.
TianeptineThe serum concentration of Tianeptine can be increased when it is combined with Perindopril.
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Perindopril is combined with Tiaprofenic acid.
TibolonePerindopril may increase the hypotensive activities of Tibolone.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Perindopril.
TicrynafenPerindopril may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Perindopril.
TinzaparinTinzaparin may increase the hyperkalemic activities of Perindopril.
TipranavirThe serum concentration of Perindopril can be decreased when it is combined with Tipranavir.
TizanidineTizanidine may increase the hypotensive activities of Perindopril.
TizanidineThe risk or severity of adverse effects can be increased when Perindopril is combined with Tizanidine.
TolazolinePerindopril may increase the hypotensive activities of Tolazoline.
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Perindopril is combined with Tolfenamic Acid.
TolmetinThe risk or severity of adverse effects can be increased when Perindopril is combined with Tolmetin.
ToloxatoneToloxatone may increase the hypotensive activities of Perindopril.
TolvaptanTolvaptan may increase the hyperkalemic activities of Perindopril.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Perindopril.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Perindopril.
TorasemideTorasemide may increase the hypotensive activities of Perindopril.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Perindopril.
TrandolaprilTrandolapril may increase the hypotensive activities of Perindopril.
TranilastThe risk or severity of adverse effects can be increased when Perindopril is combined with Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Perindopril.
TranylcypromineTranylcypromine may increase the hypotensive activities of Perindopril.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Perindopril.
TravoprostTravoprost may increase the hypotensive activities of Perindopril.
TreprostinilTreprostinil may increase the hypotensive activities of Perindopril.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Perindopril.
TriazolamThe serum concentration of Triazolam can be increased when it is combined with Perindopril.
TrichlormethiazidePerindopril may increase the hypotensive activities of Trichlormethiazide.
TrimazosinPerindopril may increase the hypotensive activities of Trimazosin.
TrimethaphanPerindopril may increase the hypotensive activities of Trimethaphan.
TrimethoprimTrimethoprim may increase the hyperkalemic activities of Perindopril.
TrimipramineThe serum concentration of Trimipramine can be increased when it is combined with Perindopril.
Trisalicylate-cholineThe risk or severity of adverse effects can be increased when Perindopril is combined with Trisalicylate-choline.
UdenafilUdenafil may increase the antihypertensive activities of Perindopril.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Perindopril.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Perindopril.
UnoprostonePerindopril may increase the hypotensive activities of Unoprostone.
ValdecoxibThe risk or severity of adverse effects can be increased when Perindopril is combined with Valdecoxib.
ValsartanValsartan may increase the hypotensive activities of Perindopril.
VardenafilVardenafil may increase the antihypertensive activities of Perindopril.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Perindopril.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Perindopril.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Perindopril.
VildagliptinThe risk or severity of adverse effects can be increased when Vildagliptin is combined with Perindopril.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Perindopril.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Perindopril.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Perindopril.
XylometazolinePerindopril may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Perindopril.
ZaltoprofenThe risk or severity of adverse effects can be increased when Perindopril is combined with Zaltoprofen.
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Perindopril.
ZileutonThe risk or severity of adverse effects can be increased when Perindopril is combined with Zileuton.
ZomepiracThe risk or severity of adverse effects can be increased when Perindopril is combined with Zomepirac.
Food Interactions
  • Herbs that may attenuate the antihypertensive effect of perindopril include: bayberry, blue cohash, cayenne, ephedra, ginger, ginseng (American), kola and licorice.
  • High salt intake may attenuate the antihypertensive effect of perindopril.
  • Perindopril may decrease the excretion of potassium. Salt substitutes containing potassium may increase the risk of hyperkalemia.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Zinc ion binding
Specific Function:
Converts angiotensin I to angiotensin II by release of the terminal His-Leu, this results in an increase of the vasoconstrictor activity of angiotensin. Also able to inactivate bradykinin, a potent vasodilator. Has also a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety.
Gene Name:
ACE
Uniprot ID:
P12821
Molecular Weight:
149713.675 Da
References
  1. Alfakih K, Hall AS: Perindopril. Expert Opin Pharmacother. 2006 Jan;7(1):63-71. [PubMed:16370923 ]
  2. Brugts JJ, Ferrari R, Simoons ML: Angiotensin-converting enzyme inhibition by perindopril in the treatment of cardiovascular disease. Expert Rev Cardiovasc Ther. 2009 Apr;7(4):345-60. doi: 10.1586/erc.09.2. [PubMed:19379059 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
  4. Song JC, White CM: Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors: an update. Clin Pharmacokinet. 2002;41(3):207-24. [PubMed:11929321 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Mehta A, Iyer L, Parmar S, Shah G, Goyal R: Oculohypotensive effect of perindopril in acute and chronic models of glaucoma in rabbits. Can J Physiol Pharmacol. 2010 May;88(5):595-600. doi: 10.1139/y10-026. [PubMed:20555429 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Proton-dependent oligopeptide secondary active transmembrane transporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides. May constitute a major route for the absorption of protein digestion end-products.
Gene Name:
SLC15A1
Uniprot ID:
P46059
Molecular Weight:
78805.265 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Peptide:proton symporter activity
Specific Function:
Proton-coupled intake of oligopeptides of 2 to 4 amino acids with a preference for dipeptides.
Gene Name:
SLC15A2
Uniprot ID:
Q16348
Molecular Weight:
81782.77 Da
References
  1. Knutter I, Wollesky C, Kottra G, Hahn MG, Fischer W, Zebisch K, Neubert RH, Daniel H, Brandsch M: Transport of angiotensin-converting enzyme inhibitors by H+/peptide transporters revisited. J Pharmacol Exp Ther. 2008 Nov;327(2):432-41. doi: 10.1124/jpet.108.143339. Epub 2008 Aug 19. [PubMed:18713951 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 27, 2016 02:28